PharmaMar is present at the 16th International Gynecologic Cancer Society Meeting with new evidence on Yondelis®

Madrid, October 31th, 2016.- PharmaMar (MSE:PHM) presents the new data obtained from several clinical studies carried out with its antitumor compound of marine origin, Yondelis®, during the 16th Biennial International Gynecologic Cancer Society Meeting (IGCS) that is taking place in Lisbon, Portugal, from the 29th to the 31st of October.

Through several presentations, PharmaMar is highlighting the role of trabectedin in platinum-sensitive ovarian cancer patients. It has been presented an overall survival analysis of the patients with relapsed ovarian cancer treated with platinum, compared to non-platinum treatments after receiving trabectedin in combination with pegylated liposomal doxorubicin (PLD) or PLD as a single agent; as well as a Phase II clinical trial that suggests that trabectedin in combination with bevacizumab may provide a promising regimen in patients that are partially sensitive to platinum in relapsed ovarian cancer.

Apart from presenting clinical data results, PharmaMar presents a cost-comparison study on trabectedin plus PLD –at first relapse- followed by platinum based chemotherapy in comparison to bevacizumab-based maintenance schema in first line patients with a high risk of ovarian cancer. As a principal conclusion, it can be observed that the survival rate achieved by both is tantamount, although the cost of the trabectedin regimen is lower.

To finish with, PharmaMar has organized a satellite symposium entitled ‘Managing relapsed ovarian cancer in a rapidly evolving landscape’ in which international experts will analyze, amongst other subjects, at which moment it is convenient to use platinum; the role of trabectedin + PLD when it is not convenient to treat patients with a new treatment with platinum; and the treatments of ovarian cancer taking into account the 2015 Tokyo International Consensus of the Gynecological Cancer Intergroup and daily clinical practice.

Main studies that PharmaMar presents at IGCS 2016
Yondelis® (trabectedin)

- **OS analysis by treatments received after trabectedin/PLD or PLD alone in patients with recurrent ovarian cancer: Platinum vs. non-platinum (OVA-301)**
  e-poster. Lead author: Andrés Poveda, MD, et al. Valencia Institute of Oncology, Spain

- **Randomized, non-comparative, phase II trial of bevacizumab and trabectedin with or without carboplatin in platinum partially-sensitive recurring ovarian cancer women (IRFMN-OVA-6152 study)**
  Oral session e-poster. Lead author: Prof. Nicoletta Colombo, PhD, et al. Instituto Europeo de Oncología, Milan, Italy

- **Audit of trabectedin use in high grade serous carcinoma**
  e-poster. Lead author: S. Thair, MD, et al. Broomfield Hospital, Oncology, Chelmsford, United Kingdom

- **Trabectedin in heavily pretreated recurrent ovarian cancer patients: a case-control study**
  e-poster. Lead author: Prof. P. Benedetti Panici, et al, Policlinico Umberto I - Sapienza University of Rome, Italy

- **Trabectedin plus pegylated liposomal doxorubicin –at first relapse-followed by platinum based chemotherapy versus bevacizumab-based maintenance schema in first line, high-risk ovarian cancer patients: a cost-comparison study**
  e-poster. Lead authors: J.M. Fernández Santos, PharmaMar, Colmenar Viejo, Madrid; J.M. del Campo, Diagonal clinic, Barcelona, Spain

**About YONDELIS® (trabectedin)**

YONDELIS® (trabectedin) is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, *Ecteinascidia turbinata*. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. It is approved in close 80 countries in North America, Europe, South America and Asia for the treatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian cancer in combination with DOXIL®/CAELYX® (doxorubicin HCl liposome injection) in
the European Union. Under a licensing agreement with PharmaMar, Janssen Products, L.P. has the rights to develop and sell YONDELIS® globally except in Europe, where PharmaMar holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceuticals.

About PharmaMar
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer
This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:
Paula Fdez. Alarcón – Media Relations Manager
pfalarcon@pharmamar.com
Phone: +34 91 846 6000 / +34 638796215

Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com